V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213868 | 20080243 | 1.9 | 76.5 | Curative (C) | 2015-09-19 | 2015-10-10 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100329853 |
| 20213869 | 20080244 | null | 68.8 | 03 | 2020-01-17 | 2020-01-22 | LANREOTIDE | N | N | LANREOTIDE | 101151827 |
| 20213870 | 20080245 | 1.77 | 74 | 03 | 2018-08-18 | 2018-10-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101413320 |
| 20213871 | 20080246 | 1.49 | 73.1 | Palliative (P) | null | 2015-02-17 | null | 02 | N | TRIAL | 101519771 |
| 20213872 | 20080247 | 1.7 | 126 | Curative (C) | 2017-07-03 | 2017-07-31 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100502387 |
| 20213873 | 20080248 | null | 82 | Disease modification (D) | 2020-02-03 | 2020-02-04 | LANREOTIDE | 02 | N | LANREOTIDE | 100647936 |
| 20213874 | 20080249 | 1.61 | 0 | Palliative (P) | 2018-04-02 | 2018-04-09 | Trial Unspecified | 02 | N | TRIAL | 100979693 |
| 20213875 | 20080250 | 1.76 | 90.5 | Palliative (P) | 2019-08-01 | 2019-08-01 | CAPECITABINE + CISPLATIN + Trastuzumab | null | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101126725 |
| 20213876 | 20080251 | 1.62 | 97.65 | Disease modification (D) | 2018-11-13 | 2018-12-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101468581 |
| 20213877 | 20080252 | null | 0 | Palliative (P) | null | 2013-09-21 | null | null | N | LANREOTIDE | 101478941 |
| 20213878 | 20080253 | null | null | Palliative (P) | 2021-10-23 | 2021-11-07 | LANREOTIDE | 02 | N | LANREOTIDE | 100001202 |
| 20213879 | 20080254 | null | 98.7 | Neo-adjuvant (N) | 2019-01-06 | 2019-01-14 | Imatinib 400mg | N | N | IMATINIB | 101830755 |
| 20213880 | 20080255 | 1.54 | 0 | null | 2016-05-05 | 2016-05-13 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101085669 |
| 20213881 | 20080256 | null | 49.1 | null | 2018-09-04 | 2018-09-11 | LANREOTIDE | 02 | null | LANREOTIDE | 101041322 |
| 20213882 | 20080257 | 1.6 | 66 | Palliative (P) | 2016-09-30 | 2016-09-30 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101227921 |
| 20213883 | 20080258 | 1.6 | 67.7 | null | 2018-08-14 | 2018-08-14 | Imatinib 400mg | 02 | null | IMATINIB | 101063353 |
| 20213884 | 20080259 | 1.69 | null | Palliative (P) | null | 2016-10-19 | GO2 TRIAL | 1 | N | TRIAL | 100196364 |
| 20213885 | 20080260 | 1.67 | 84.6 | Curative (C) | 2016-03-18 | 2016-04-06 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101257790 |
| 20213886 | 20080261 | 1.78 | 0 | Palliative (P) | 2018-12-15 | 2018-12-15 | IMATINIB | 02 | N | IMATINIB | 100509448 |
| 20213887 | 20080262 | 1.62 | 70.4 | Palliative (P) | 2019-08-19 | 2019-08-26 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100962054 |
| 20213888 | 20080263 | 1.8 | 70.2 | null | 2020-02-05 | 2020-02-25 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100088430 |
| 20213889 | 20080264 | 0 | 0 | Neo-adjuvant (N) | 2018-06-30 | 2018-07-06 | Cape+Cisplatin+Trastuzumab Main | 02 | N | IMATINIB | 101379461 |
| 20213890 | 20080265 | 1.6 | 72.8 | Palliative (P) | 2018-04-09 | 2018-04-20 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100175147 |
| 20213892 | 20080266 | 1.59 | 69.9 | Palliative (P) | 2019-03-25 | 2019-03-25 | Trial Unspecified | Y | N | TRIAL | 101044936 |
| 20213893 | 20080267 | 1.77 | 68.3 | Palliative (P) | 2018-02-14 | 2018-03-12 | GO2 TRIAL | 1 | N | TRIAL | 101633916 |
| 20213894 | 20080268 | 1.57 | null | Curative (C) | 2018-10-14 | 2018-10-17 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100417374 |
| 20213895 | 20080269 | 1.67 | 58 | Palliative (P) | 2019-11-16 | 2019-11-25 | Cape+Cisplatin+Trastuzumab Main | 02 | N | TRIAL | 101615898 |
| 20213898 | 20080270 | 1.8 | 95.7 | null | 2018-04-06 | 2018-05-03 | LANREOTIDE | 02 | null | LANREOTIDE | 100396445 |
| 20213899 | 20080271 | 1.75 | 81.75 | 03 | 2016-06-20 | 2016-07-06 | Cape+Cisplatin+Trastuzumab Load | 01 | N | IMATINIB | 100449925 |
| 20213900 | 20080272 | 1.69 | 72.6 | Curative (C) | 2019-06-04 | 2019-06-09 | HCX (Cape + Cisp + Tras) - Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100200612 |
| 20213902 | 20080273 | 1.75 | 76.3 | Adjuvant (A) | 2019-12-24 | 2020-01-13 | Cape+Cisplatin+Trastuzumab Load | 02 | N | IMATINIB | 100370319 |
| 20213904 | 20080275 | 1.69 | 104.6 | Palliative (P) | 2017-08-30 | 2017-08-30 | Trial Unspecified | Y | N | TRIAL | 101225462 |
| 20213905 | 20080276 | null | 65 | null | 2018-04-25 | 2018-04-27 | IMATINIB | 02 | null | IMATINIB | 100893291 |
| 20213906 | 20080277 | 1.7 | 118.6 | Palliative (P) | 2019-01-08 | 2019-02-06 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100452246 |
| 20213907 | 20080278 | 1.8 | 86.3 | Adjuvant (A) | 2017-11-12 | 2017-11-20 | HCX | 02 | null | IMATINIB | 100065102 |
| 20213911 | 20080280 | 1.73 | 47.1 | null | 2019-08-13 | 2019-08-13 | IMATINIB | N | null | IMATINIB | 100504495 |
| 20213912 | 20080281 | 1.62 | 82.2 | Palliative (P) | 2018-04-15 | 2018-04-27 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100816037 |
| 20213913 | 20080282 | 1.76 | 75.9 | Curative (C) | 2018-11-16 | 2018-12-11 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101430188 |
| 20213914 | 20080283 | 1.54 | 84.4 | Palliative (P) | 2018-06-22 | 2018-07-20 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100786720 |
| 20213918 | 20080284 | 1.67 | 77.2 | Curative (C) | 2019-06-21 | 2019-07-10 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101506247 |
| 20213920 | 20080285 | 1.5 | 73.1 | Curative (C) | 2017-12-20 | 2018-01-09 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101097155 |
| 20213921 | 20080286 | 1.63 | 0 | Curative (C) | 2017-07-17 | 2017-07-17 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101809154 |
| 20213922 | 20080287 | 1.6 | null | Curative (C) | 2018-09-23 | 2018-10-21 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100644538 |
| 20213924 | 20080288 | 1.68 | 70.8 | Curative (C) | null | 2019-05-24 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101376638 |
| 20213925 | 20080289 | 0 | 67.5 | Palliative (P) | 2018-07-18 | 2018-07-30 | HCX (Cape + Cisp + Tras) - Load | 02 | N | LANREOTIDE | 101691490 |
| 20213926 | 20080290 | 1.77 | 52.8 | Adjuvant (A) | 2019-05-25 | 2019-06-08 | HCX | 02 | N | IMATINIB | 100548328 |
| 20213927 | 20080291 | 1.49 | 93.45 | null | 2016-09-07 | 2016-09-15 | LANREOTIDE | 02 | null | LANREOTIDE | 101285813 |
| 20213929 | 20080292 | 1.78 | 93.7 | Curative (C) | null | 2016-08-16 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101191174 |
| 20213930 | 20080293 | 1.69 | 73 | null | 2018-07-29 | 2018-07-29 | LANREOTIDE | 02 | null | LANREOTIDE | 101283251 |
| 20213931 | 20080294 | 1.62 | 47 | Palliative (P) | 2017-06-22 | 2017-06-22 | Trial Unspecified | 1 | N | TRIAL | 100954852 |